| Market Capitalization (Millions $) |
2 |
| Shares
Outstanding (Millions) |
7 |
| Employees |
18 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-8 |
| Cash Flow (TTM) (Millions $) |
-8 |
| Capital Exp. (TTM) (Millions $) |
0 |
Oragenics Inc
Oragenics Inc is a bio-pharmaceutical company that is involved in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in the United States, and its main focus is to create high-quality products to address major global health concerns.
Oragenics Inc's core technology is based on a proprietary platform called Oral Care and Therapeutics (OCAT). This platform is designed to develop drugs to tackle oral diseases by targeting the specific bacteria that are responsible for causing them. The OCAT platform uses recombinant DNA technology to generate beneficial microbes that can compete with and eradicate pathogenic bacteria.
The company's lead product candidate is TerraCoV2, which is a COVID-19 vaccine that uses its OCAT platform to develop a protein expression technology to generate recombinant spike proteins. This vaccine candidate is in preclinical development.
Oragenics Inc is also developing AG013, an oral mucositis treatment that uses the OCAT platform to generate a live biotherapeutic product that produces human tissue repair factors. This drug candidate is currently in Phase II clinical trials.
Another product candidate in the company's pipeline is OG716, which is an oral care product aimed at reducing the risk of dental caries. This product is a bacteriocin that uses the OCAT platform to generate a peptide that can selectively kill specific pathogenic bacteria without harming the beneficial bacteria.
In addition to its product development efforts, Oragenics Inc has established several partnerships with leading research institutions and pharmaceutical companies. These collaborations are focused on leveraging the company's technology and expertise to advance the development of disease vaccines, therapeutics, and diagnostic tools.
Overall, Oragenics Inc is a leading bio-pharmaceutical company that is dedicated to developing innovative products to address major global health concerns. With a strong pipeline of products and ongoing collaborations, the company is well-positioned to make a significant impact on the field of infectious disease therapeutics.
Company Address: 1990 Main Street Sarasota 34236 FL
Company Phone Number: 286-7900 Stock Exchange / Ticker: NYSEAMER OGEN
|
1.8% 